- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Cases selected for the AskAnzal weekly PMCPA insight newsletter
PMCPA case AUTH/2895/11/16 (Director v Boehringer Ingelheim) concerning clinical trial disclosure for Giotrif. Outcome: No breach; matter was…
Complaint alleged a third-party email linked GSK-sponsored COPD therapy reviews to “client product/therapy priorities”. Panel and Appeal Board…
Novartis-funded third‑party “medical education” videos were ruled promotional for unlicensed inclisiran, lacked clear sponsorship disclosure and certification, and…
BMJ ad framed as an acquisition announcement for Dificlir was ruled promotional. It lacked prescribing information and an…
Forxiga website and rep messaging implied all patients can start 10mg with no uptitration. Key 5mg start for…
A third-party promotional webpage had a non-functioning single-click PI link for Pradaxa/Praxbind for ~3 weeks. An earlier email…
Six amalgamated complaints. Breaches found for a UK “think tank” meeting (uncertified promotional content; ‘cure’ implication) and LinkedIn…
Complaint alleged a senior employee’s LinkedIn ‘Experience’ section promoted Enhertu to the public and off-label, using terms like…
An anonymous representative alleged pressure to promote Aldara off-licence and raised concerns about call-rate targets and a GP…
Novartis’ UK press release headline implied an overall survival benefit for Femara vs tamoxifen despite non-significant ITT results…
One real case. One key lesson. Every week — free.